The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noaf102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Zhiyi Xue und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Cheeloo College of Medicine, Qilu Hospital, Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Brain Neoplasms, Radiation-Sensitizing Agents, Ataxia Telangiectasia Mutated Proteins, Protein Kinase Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
The ataxia-telangiectasia mutated (ATM) protein coordinates the cellular response to therapeutic radiation, and ATM inhibitors can potentially enhance the efficacy of radiation in otherwise radiation-resistant tumors.
Methods
The small molecule ATM kinase inhibitor WSD0628 was specifically designed for enhanced distribution across the blood-brain barrier to more effectively treat glioblastoma (GBM) and brain metastases in combination with radiation therapy (RT). GBM and brain metastasis patient-derived xenograft models were used to understand target inhibition, radiosensitization, inhibition of the DNA damage response, and in vivo efficacy.
Results
Initial in vitro characterization of WSD0628 demonstrates a high level of selectivity across kinase families, limited aldehyde oxidase liability, and low risk of hERG interactions. Consistent with a central role for ATM in radiation response, WSD0628 blocked radiation-induced signaling and enhanced radiosensitivity in U251 glioma cells and brain tumor PDXs GBM120 and M12. In comparison to control or RT alone in orthotopic PDXs, the combination of WSD0628 with RT markedly prolonged median survival—GBM12 (19, 55, and 408 days, respectively); GBM43 (26, 44, and 143 days, respectively); GBM120 (51, 89, and 231 days, respectively); M12 (17, 39, and 190 days, respectively). Pharmacokinetic and pharmacodynamic testing after treatment in orthotopic GBM43 tumors showed inhibitory levels of WSD0628 and a reduction of γH2AX foci in the combination-treated tumors.
Conclusions
Collectively, these results suggest a promising role for WSD0628 in combination with RT in brain tumors and provide the rationale for an ongoing Phase 0/1A clinical trial testing this combination in recurrent GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Cheeloo College of Medicine, Qilu Hospital, Shandong University, Jinan, China.
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
- Wayshine Biopharm Inc, Corona, California, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Paul A Decker, Jann N Sarkaria
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Xue, Z., Mladek, A. C., Rathi, S., Jain, S., Vaubel, R. A., Odukoya, L. A., Garcia, D. A., Liu, L., Bakken, K. K., Carlson, B. L., Ott, L. L., Burgenske, D. M., Hu, Z., Dragojevic, S., Decker, P. A., Kosel, M. L., Breen, W. G., Gupta, S. K., Eckel-Passow, J. E., …, & Sarkaria, J. N. (2025). The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf102
Vancouver
Xue Z, Mladek AC, Rathi S, Jain S, Vaubel RA, Odukoya LA, et al. The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf102
BibTeX
@article{Xue2025,
author = {Xue, Zhiyi and Mladek, Ann C and Rathi, Sneha and Jain, Sonia and Vaubel, Rachael A and Odukoya, Lateef A and Garcia, Darwin A and Liu, Lily and Bakken, Katrina K and Carlson, Brett L and Ott, Lauren L and Burgenske, Danielle M and Hu, Zeng and Dragojevic, Sonja and Decker, Paul A and Kosel, Matthew L and Breen, William G and Gupta, Shiv K and Eckel-Passow, Jeanette E and Elmquist, William F and Zhong, Wei and Sarkaria, Jann N},
title = {The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noaf102}
}
EUVIMED